{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:42:24Z","timestamp":1777923744932,"version":"3.51.4"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T00:00:00Z","timestamp":1416960000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s10822-014-9816-1","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T14:17:40Z","timestamp":1417443460000},"page":"183-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Predicting targets of compounds against neurological diseases using cheminformatic methodology"],"prefix":"10.1007","volume":"29","author":[{"given":"Katarina","family":"Nikolic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lazaros","family":"Mavridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar M.","family":"Bautista-Aguilera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Marco-Contelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"do Carmo Carreiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Massarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danica","family":"Agbaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rona R.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B. O.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,26]]},"reference":[{"key":"9816_CR1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.1132814","volume":"314","author":"M Goedert","year":"2006","unstructured":"Goedert M, Spillantini MGA (2006) A century of Alzheimer\u2019s disease. Science 314:777\u2013781","journal-title":"Science"},{"key":"9816_CR2","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bcp.2007.01.006","volume":"73","author":"M Humbert-Claude","year":"2007","unstructured":"Humbert-Claude M, Morisset S, Gbahou F, Arrang JM (2007) Histamine H3 and dopamine D2 receptor-mediated [35S]GTP\u03b3[S] binding in rat striatum: evidence for additive effects but lack of interactions. Biochem Pharmacol 73:1172\u20131181","journal-title":"Biochem Pharmacol"},{"key":"9816_CR3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.neuropharm.2006.08.001","volume":"52","author":"B Garduno-Torres","year":"2007","unstructured":"Garduno-Torres B, Trevino M, Gutierrez R, Arias-Montano JA (2007) Presynaptic histamine H3 receptors regulate glutamate, but not GABA release in rat thalamus. Neuropharmacology 52:527\u2013535","journal-title":"Neuropharmacology"},{"key":"9816_CR4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2007.01.069","volume":"563","author":"H Dai","year":"2007","unstructured":"Dai H, Fu Q, Shen Y, Hu W, Zhang Z, Timmerman H, Leurs R, Chen Z (2007) The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA induced excitotoxicity through the cAMP\/protein kinase A pathway in cultured cortical neurons. Eur J Pharmacol 563:117\u2013123","journal-title":"Eur J Pharmacol"},{"key":"9816_CR5","doi-asserted-by":"crossref","first-page":"8704","DOI":"10.1523\/JNEUROSCI.2690-04.2004","volume":"24","author":"S Threlfell","year":"2004","unstructured":"Threlfell S, Cragg SJ, Imre K, Turi GF, Coen CW, Greenfield SA (2004) Histamine H3 receptors inhibit serotonin release in substantia nigra pars reticulata. J Neurosci 24:8704\u20138710","journal-title":"J Neurosci"},{"key":"9816_CR6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.drudis.2009.02.011","volume":"14","author":"MJ Gemkow","year":"2009","unstructured":"Gemkow MJ, Davenport AJ, Harich S, Ellenbroek BA, Cesura A, Hallett D (2009) The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today 14:509\u2013515","journal-title":"Drug Discov Today"},{"key":"9816_CR7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/med.20248","volume":"33","author":"R Le\u00f3n","year":"2013","unstructured":"Le\u00f3n R, Garcia AG, Marco-Contelles J (2013) Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer\u2019s disease. Med Res Rev 33:139\u2013189","journal-title":"Med Res Rev"},{"key":"9816_CR8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1017\/S1461145712001496","volume":"17","author":"MJ Millan","year":"2014","unstructured":"Millan MJ (2014) On \u2018polypharmacy\u2019 and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. Int J Neuropsychopharmacol 17:1009\u20131037","journal-title":"Int J Neuropsychopharmacol"},{"key":"9816_CR9","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","volume":"57","author":"A Anighoro","year":"2014","unstructured":"Anighoro A, Bajorath J, Rastelli G (2014) Polypharmacology: challenges and opportunities in drug discovery. J Med Chem 57:7874\u20137887","journal-title":"J Med Chem"},{"key":"9816_CR10","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","volume":"48","author":"R Morphy","year":"2005","unstructured":"Morphy R, Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48:6523\u20136543","journal-title":"J Med Chem"},{"key":"9816_CR11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","volume":"3","author":"BL Roth","year":"2004","unstructured":"Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353\u2013359","journal-title":"Nat Rev Drug Discov"},{"key":"9816_CR12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neuropharm.2012.06.032","volume":"64","author":"TV Lipina","year":"2013","unstructured":"Lipina TV, Palomo V, Gil C, Martinez A, Roder JC (2013) Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL\/6J mice. Neuropharmacology 64:205\u2013214","journal-title":"Neuropharmacology"},{"key":"9816_CR13","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.neuropharm.2011.02.020","volume":"62","author":"TV Lipina","year":"2012","unstructured":"Lipina TV, Wang M, Liu F, Roder JC (2012) Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice. Neuropharmacology 62:1252\u20131262","journal-title":"Neuropharmacology"},{"key":"9816_CR14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2005.11.006","volume":"110","author":"MJ Millan","year":"2006","unstructured":"Millan MJ (2006) Multi-target strategies for the improved treatment of depressive states: conceptual foundation and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110:135\u2013370","journal-title":"Pharmacol Ther"},{"key":"9816_CR15","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.2174\/138920112800784880","volume":"13","author":"HY Meltzer","year":"2012","unstructured":"Meltzer HY, Massey BW, Horiguchi M (2012) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 13:1572\u20131586","journal-title":"Curr Pharm Biotechnol"},{"key":"9816_CR16","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1517\/13543784.2012.719872","volume":"21","author":"G Quesseveur","year":"2012","unstructured":"Quesseveur G, Nguyen HT, Gardier AM, Guiard BP (2012) 5-HT2 ligands in the treatment of anxiety and depression. Expert Opin Investig Drugs 21:1701\u20131725","journal-title":"Expert Opin Investig Drugs"},{"key":"9816_CR17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tips.2004.11.007","volume":"26","author":"MBH Youdim","year":"2005","unstructured":"Youdim MBH, Buccafusco JJ (2005) Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26:27\u201335","journal-title":"Trends Pharmacol Sci"},{"key":"9816_CR18","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1021\/jm301034u","volume":"55","author":"T Tahtouh","year":"2012","unstructured":"Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E, Cochet C, Schmid RS, Lo DC, Delhommel F, Oberholzer AE, Pearl LH, Carreaux F, Bazureau JP, Knapp S, Meijer L (2012) Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem 55:9312\u20139330","journal-title":"J Med Chem"},{"key":"9816_CR19","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1021\/jm030952q","volume":"46","author":"M Rosini","year":"2003","unstructured":"Rosini M, Antonello A, Cavalli A, Bolognesi ML, Minarini A, Marucci G, Poggesi E, Leonardi A, Melchiorre C (2003) Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for \u03b11-adrenoreceptors. J Med Chem 46:4895\u20134903","journal-title":"J Med Chem"},{"key":"9816_CR20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/jm701491k","volume":"51","author":"L Fang","year":"2008","unstructured":"Fang L, Appenroth D, Decker M, Kiehntopf M, Roegler C, Deufel T, Fleck C, Peng S, Zhang Y, Lehmann J (2008) Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J Med Chem 51:713\u2013716","journal-title":"J Med Chem"},{"key":"9816_CR21","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1021\/jm400336x","volume":"56","author":"A Stosel","year":"2013","unstructured":"Stosel A, Schlenk M, Hinz S, Kuppers P, Heer J, Gutschow M, Muller CE (2013) Dual targeting of adenosine A2A receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones. J Med Chem 56:4580\u20134596","journal-title":"J Med Chem"},{"key":"9816_CR22","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.bmcl.2008.03.073","volume":"18","author":"L Fang","year":"2008","unstructured":"Fang L, Kraus B, Lehmann J, Heilmann J, Zhang Y, Decker M (2008) Design and synthesis of tacrine\u2013ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg Med Lett 18:2905\u20132909","journal-title":"Bioorg Med Lett"},{"key":"9816_CR23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbapap.2013.11.003","volume":"1844","author":"JJ Jim\u00e9nez","year":"2014","unstructured":"Jim\u00e9nez JJ, Mendes E, Galdeano C, Martins C, Silva DB, Marco-Contelles J, Carmo Carreiras M, Luque FJ, Ramsay RR (2014) Exploring the structural basis of the selective inhibition of monoamine oxidase A by dicarbonitrile aminoheterocycles: role of Asn181 and Ile335 validated by spectroscopic and computational studies. Biochim Biophys Acta 1844:389\u2013397","journal-title":"Biochim Biophys Acta"},{"key":"9816_CR24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejmech.2013.12.028","volume":"75","author":"OM Bautista-Aguileraa","year":"2014","unstructured":"Bautista-Aguileraa OM, Estebanb G, Bolea I, Nikolic K, Agbaba D, Moraleda I, Iriepa I, Samadi A, Soriano E, Unzeta M, Marco-Contelles J (2014) Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil\u2013indolyl hybrids as multipotent cholinesterase\/monoamine oxidase inhibitors for the potential treatment of Alzheimer\u2019s disease. Eur J Med Chem 75:82\u201395","journal-title":"Eur J Med Chem"},{"key":"9816_CR25","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1016\/j.ejmech.2011.05.048","volume":"46","author":"A Samadi","year":"2011","unstructured":"Samadi A, Chioua M, Bolea I, de los R\u00edos C, Iriepa I, Moraleda I, Bastida A, Esteban G, Unzeta M, G\u00e1lvez E, Marco-Contelles J (2011) Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 46:4665\u20134668","journal-title":"Eur J Med Chem"},{"key":"9816_CR26","doi-asserted-by":"crossref","first-page":"8251","DOI":"10.1021\/jm200853t","volume":"54","author":"I Bolea","year":"2011","unstructured":"Bolea I, Ju\u00e1rez-Jim\u00e9nez J, R\u00edos C, Chioua M, Pouplana R, Javier Luque F, Unzeta M, Marco-Contelles J, Samadi A (2011) Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase\/monoamine oxidase inhibitors for the treatment of Alzheimer\u2019s disease. J Med Chem 54:8251\u20138270","journal-title":"J Med Chem"},{"key":"9816_CR27","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.bjp.0702600","volume":"127","author":"V P\u00e9rez","year":"1999","unstructured":"P\u00e9rez V, Marco-Contelles J, Fern\u00e1ndez-\u00c1lvarez E, Unzeta M (1999) Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br J Pharmacol 127:869\u2013876","journal-title":"Br J Pharmacol"},{"key":"9816_CR28","doi-asserted-by":"crossref","unstructured":"Marco-Contelles J, Leon R, R\u0131os C, Guglietta A, Terencio J, Lopez MG, Garc\u0131a AG, Villarroya M (2006) Novel multipotent tacrine\u2013dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer\u2019s disease. J Med Chem 49(26):7607\u20137610","DOI":"10.1021\/jm061047j"},{"key":"9816_CR29","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1021\/jm801292b","volume":"52","author":"J Marco-Contelles","year":"2009","unstructured":"Marco-Contelles J, Leon R, R\u0131os C, Samadi A, Bartolini M, Andrisano V, Huertas O, Barril X, Luque FJ, Rodr\u0131guez-Franco MI, Lopez B, Lopez MG, Garc\u0131a AG, Carmo Carreiras M, Villarroya M (2009) Tacripyrines, the first tacrine\u2013dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer\u2019s disease. J Med Chem 52:2724\u20132732","journal-title":"J Med Chem"},{"key":"9816_CR30","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1021\/jm0110845","volume":"45","author":"J Apelt","year":"2002","unstructured":"Apelt J, Ligneau X, Pertz H, Arrang JM, Ganellin CR, Schwartz JC, Schunack W, Holger S (2002) Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity. J Med Chem 45:1128\u20131141","journal-title":"J Med Chem"},{"key":"9816_CR31","first-page":"179","volume":"61","author":"G Petroianu","year":"2006","unstructured":"Petroianu G, Arafat K, Sasse BC, Stark H (2006) Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents. Pharmazie 61:179\u2013182","journal-title":"Pharmazie"},{"key":"9816_CR32","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0968-0896(03)00120-2","volume":"11","author":"S Grassmann","year":"2003","unstructured":"Grassmann S, Apelt J, Sippl W, Ligneau X, Pertz HH, Zhao YH, Arrang JM, Ganellin CR, Schwartz JC, Schunack W, Stark H (2003) Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine H3 receptor affinities. Bioorg Med Chem 11:2163\u20132174","journal-title":"Bioorg Med Chem"},{"key":"9816_CR33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ardp.200400897","volume":"337","author":"S Grassmann","year":"2004","unstructured":"Grassmann S, Apelt J, Ligneau X, Pertz HH, Arrang JM, Schwartz JC, Schunack W, Stark H (2004) Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: omega-piperidinoalkanamine derivatives. Arch Pharm Med Chem 337:533\u2013545","journal-title":"Arch Pharm Med Chem"},{"key":"9816_CR34","first-page":"97","volume":"60","author":"J Apelt","year":"2005","unstructured":"Apelt J, Grassmann S, Ligneau X, Pertz HH, Ganellin CR, Arrang JM, Schwartz JC, Schunack W, Stark H (2005) Search for histamine H3 receptor antagonists with combined inhibitory potency at Ntau-methyltransferase: ether derivatives. Pharmazie 60:97\u2013106","journal-title":"Pharmazie"},{"key":"9816_CR35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-3565(24)37840-1","volume":"287","author":"X Ligneau","year":"1998","unstructured":"Ligneau X, Lin JS, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz JC (1998) Neurochemical and behavioural effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 287:658\u2013666","journal-title":"J Pharmacol Exp Ther"},{"key":"9816_CR36","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1248\/bpb.31.2163","volume":"31","author":"K Sander","year":"2008","unstructured":"Sander K, Kottke T, Stark H (2008) Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 31:2163\u20132181","journal-title":"Biol Pharm Bull"},{"key":"9816_CR37","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/bjp.2008.147","volume":"154","author":"TA Esbenshade","year":"2008","unstructured":"Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD (2008) The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 154:1166\u20131181","journal-title":"Br J Pharmacol"},{"key":"9816_CR38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0079-6123(08)00903-5","volume":"172","author":"G Giovanni Di","year":"2008","unstructured":"Di Giovanni G, Di Matteo V, Pierucci M, Esposito E (2008) Serotonin\u2013dopamine interaction: electrophysiological evidence. Prog Brain Res 172:45\u201371","journal-title":"Prog Brain Res"},{"key":"9816_CR39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0079-6123(08)00902-3","volume":"172","author":"V Matteo Di","year":"2008","unstructured":"Di Matteo V, Di Giovanni G, Pierucci M, Esposito E (2008) Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog Brain Res 172:7\u201344","journal-title":"Prog Brain Res"},{"key":"9816_CR40","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0166-2236(90)90108-M","volume":"13","author":"M Carlsson","year":"1990","unstructured":"Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia\u2014implications for schizophrenia and Parkinson \u2018s disease. Trends Neurosci 13:272\u2013276","journal-title":"Trends Neurosci"},{"key":"9816_CR41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00213-005-2199-1","volume":"179","author":"MJ Millan","year":"2005","unstructured":"Millan MJ (2005) N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 179:30\u201353","journal-title":"Psychopharmacology"},{"key":"9816_CR42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1527-3458.2003.tb00254.x","volume":"9","author":"MA Rogawski","year":"2003","unstructured":"Rogawski MA, Wenk GL (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer\u2019s disease. CNS Drug Rev 9:275\u2013308","journal-title":"CNS Drug Rev"},{"key":"9816_CR43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K (2014) Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6:37","journal-title":"Alzheimers Res Ther"},{"key":"9816_CR44","doi-asserted-by":"crossref","unstructured":"Zheng H, Youdim MBH, Fridkin M (2009) Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer\u2019s therapy. J Med Chem 52:4095\u20134098","DOI":"10.1021\/jm900504c"},{"key":"9816_CR45","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","volume":"51","author":"A Cavalli","year":"2008","unstructured":"Cavalli A, Bolognesi ML, Minarini M, Rosini V, Tumiatti M, Recanatini C, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51:347\u2013372","journal-title":"J Med Chem"},{"key":"9816_CR46","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1021\/ci0601160","volume":"5","author":"EO Cannon","year":"2006","unstructured":"Cannon EO, Bender A, Palmer DS, Mitchell JBO (2006) Chemoinformatics-based classification of prohibited substances employed for doping in sport. J Chem Inf Model 5:2369\u20132380","journal-title":"J Chem Inf Model"},{"key":"9816_CR47","first-page":"173","volume":"5","author":"EO Cannon","year":"2006","unstructured":"Cannon EO, Mitchell JBO (2006) Classifying the World Anti-Doping Agency\u2019s 2005 prohibited list using the chemistry development kit fingerprint. Lect Notes Bioinform 5:173\u2013182","journal-title":"Lect Notes Bioinform"},{"key":"9816_CR48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1752-153X-2-3","volume":"5","author":"EO Cannon","year":"2008","unstructured":"Cannon EO, Nigsch F, Mitchell JBO (2008) Novel hybrid ultrafast shape descriptor method for use in virtual screening. Chem Central J 5:3","journal-title":"Chem Central J"},{"key":"9816_CR49","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nbt1228","volume":"5","author":"VG Paolini","year":"2006","unstructured":"Paolini VG, Shapland RHB, Van Hoorn WP, Mason JS, Hopkins AL (2006) Global mapping of pharmacological space. Nat Biotechnol 5:805\u2013815","journal-title":"Nat Biotechnol"},{"key":"9816_CR50","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/cmdc.200700026","volume":"5","author":"A Bender","year":"2007","unstructured":"Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL (2007) Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. Chem Med Chem 5:861\u2013873","journal-title":"Chem Med Chem"},{"key":"9816_CR51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.taap.2008.05.007","volume":"5","author":"F Nigsch","year":"2008","unstructured":"Nigsch F, Mitchell JBO (2008) Toxicological relationships between proteins obtained from protein target predictions of large toxicity databases. Toxicol Appl Pharmacol 5:225\u2013234","journal-title":"Toxicol Appl Pharmacol"},{"key":"9816_CR52","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1021\/ci800079x","volume":"5","author":"F Nigsch","year":"2008","unstructured":"Nigsch F, Bender A, Jenkins JL, Mitchell JBO (2008) Ligand-target prediction using winnow and naive bayesian algorithms and the implications of overall performance statistics. J Chem Inf Model 5:2313\u20132325","journal-title":"J Chem Inf Model"},{"key":"9816_CR53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","volume":"5","author":"MJ Keiser","year":"2009","unstructured":"Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KLH, Edwards DD, Shoichet BK, Roth BL (2009) Predicting new molecular targets for known drugs. Nature 5:175\u2013181","journal-title":"Nature"},{"key":"9816_CR54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/ci1001394","volume":"5","author":"S Niijima","year":"2011","unstructured":"Niijima S, Yabuuchi H, Okuno Y (2011) Cross-target view to feature selection: identification of molecular interaction features in ligand-target space. J Chem Inf Model 5:15\u201324","journal-title":"J Chem Inf Model"},{"key":"9816_CR55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature11159","volume":"5","author":"E Lounkine","year":"2012","unstructured":"Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Lavan P, Weber E, Doak AK, Cote S, Shoichet BK, Urban L (2012) Large-scale prediction and testing of drug activity on side-effect targets. Nature 5:361\u2013367","journal-title":"Nature"},{"key":"9816_CR56","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1021\/ci3000979","volume":"5","author":"VI Perez-Nueno","year":"2012","unstructured":"Perez-Nueno VI, Venkatraman V, Mavridis L, Ritchie DW (2012) Detecting drug promiscuity using gaussian ensemble screening. J Chem Inf Model 5:1948\u20131961","journal-title":"J Chem Inf Model"},{"key":"9816_CR57","first-page":"199","volume":"9","author":"RC Glen","year":"2006","unstructured":"Glen RC, Bender A, Arnby CH, Carlsson L, Boyer S, Smith J (2006) Circular fingerprints: flexible molecular descriptors with applications from physical chemistry to ADME. IDrugs 9:199\u2013204","journal-title":"IDrugs"},{"key":"9816_CR58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1758-2946-5-31","volume":"5","author":"L Mavridis","year":"2013","unstructured":"Mavridis L, Mitchell JBO (2013) Predicting the protein targets for athletic performance-enhancing substances. J Cheminform 5:31","journal-title":"J Cheminform"},{"key":"9816_CR59","doi-asserted-by":"crossref","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","volume":"5","author":"A Gaulton","year":"2012","unstructured":"Gaulton A, Bellis LJ, Bento PA, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucl Acids Res 5:D1100\u2013D1107","journal-title":"Nucl Acids Res"},{"key":"9816_CR60","doi-asserted-by":"crossref","first-page":"D1035","DOI":"10.1093\/nar\/gkq1126","volume":"5","author":"C Knox","year":"2011","unstructured":"Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Whishart DS (2011) DrugBank 3.0: a comprehensive resource for \u2018omics\u2019 research on drugs. Nucl Acids Res 5:D1035\u2013D1041","journal-title":"Nucl Acids Res"},{"key":"9816_CR61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1471-2105-14-213","volume":"14","author":"L Mavridis","year":"2013","unstructured":"Mavridis L, Nath N, Mitchell JBO (2013) PFClust: a novel parameter free clustering algorithm. BMC Bioinform 14:213","journal-title":"BMC Bioinform"},{"key":"9816_CR62","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1126\/science.132.3434.1115","volume":"5","author":"DJ Rogers","year":"1960","unstructured":"Rogers DJ, Tanimoto TT (1960) A computer program for classifying plants. Science 5:1115\u20131118","journal-title":"Science"},{"key":"9816_CR63","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1214\/aoms\/1177704472","volume":"5","author":"E Parzen","year":"1962","unstructured":"Parzen E (1962) On estimation of a probability density function and mode. Ann Math Statist 5:1065\u20131076","journal-title":"Ann Math Statist"},{"key":"9816_CR64","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1214\/aoms\/1177728190","volume":"5","author":"M Rosenblatt","year":"1956","unstructured":"Rosenblatt M (1956) Remarks on some nonparametric estimates of a density function. Ann Math Statist 5:832\u2013837","journal-title":"Ann Math Statist"},{"key":"9816_CR65","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/0005-2795(75)90109-9","volume":"5","author":"BW Matthews","year":"1975","unstructured":"Matthews BW (1975) Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim Biophys Acta 5:442\u2013451","journal-title":"Biochim Biophys Acta"},{"key":"9816_CR66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2210-6-11","volume":"6","author":"A Hamacher","year":"2006","unstructured":"Hamacher A, Weigt M, Wiese M, Hoefgen B, Lehmann J, Kassack MU (2006) Dibenzazecine compounds with a novel dopamine\/5HT2A receptor profile and 3D-QSAR analysis. BMC Pharmacol 6:11","journal-title":"BMC Pharmacol"},{"key":"9816_CR67","unstructured":"ChemAxon MarvinSketch 5.5.1.0 program (2011) Budapest, Hungary. www.chemaxon.com\/products.html"},{"key":"9816_CR68","volume-title":"The Hartree\u2013Fock method for atoms: a numerical approach","author":"CF Froese Fischer","year":"1977","unstructured":"Froese Fischer CF (1977) The Hartree\u2013Fock method for atoms: a numerical approach. Wiley, New York"},{"key":"9816_CR69","unstructured":"Frisch MJ et al (1998) Gaussian 98 (Revision A.7). Gaussian Inc., Pittsburgh"},{"key":"9816_CR70","unstructured":"Pentacle, Version 1.0.6. (2009) Molecular Discovery Ltd., Perugia, Italy. http:\/\/www.moldiscovery.com\/soft_pentacle.php"},{"key":"9816_CR71","volume-title":"Multi-and megavariate data analysis. Basic principles and applications I","year":"2001","unstructured":"Eriksson L, Johansson E, Kettaneh-Wold N, Trygg J, Wikstrom C, Wold S (eds) (2001) Multi-and megavariate data analysis. Basic principles and applications I, 2nd edn. Umetrics Academy, Ume\u00e5","edition":"2"},{"key":"9816_CR72","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/minf.201000061","volume":"29","author":"A Tropsha","year":"2010","unstructured":"Tropsha A (2010) Best practices for QSAR model development, validation, and exploitation. Mol Inf 29:476\u2013488","journal-title":"Mol Inf"},{"key":"9816_CR73","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"YC Cheng","year":"1973","unstructured":"Cheng YC, Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099\u20133108","journal-title":"Biochem Pharmacol"},{"key":"9816_CR74","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1749-6632.1949.tb27297.x","volume":"51","author":"G Scatchard","year":"1949","unstructured":"Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:660\u2013672","journal-title":"Ann NY Acad Sci"},{"key":"9816_CR75","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/0006-2952(86)90725-2","volume":"35","author":"JR Schlegel","year":"1986","unstructured":"Schlegel JR, Peroutka SJ (1986) Nucleotide interactions with 5-HT1A binding sites directly labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT). Biochem Pharmacol 35:1943\u20131949","journal-title":"Biochem Pharmacol"},{"key":"9816_CR76","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1021\/jm00104a017","volume":"35","author":"JL Herndon","year":"1992","unstructured":"Herndon JL, Ismaiel A, Ingher SP, Teitler M, Glennon RA (1992) Ketanserin analogues: structure\u2013affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem 35:4903\u20134910","journal-title":"J Med Chem"},{"key":"9816_CR77","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/07853890008998828","volume":"32","author":"MC Buhot","year":"2000","unstructured":"Buhot MC, Martin S, Segu L (2000) Role of serotonin in memory impairment. Ann Med 32:210\u2013221","journal-title":"Ann Med"},{"key":"9816_CR78","first-page":"17","volume":"174","author":"BL Roth","year":"2004","unstructured":"Roth BL, Hanizavareh SM, Blum AE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 174:17\u201324","journal-title":"Psychopharmacology"},{"key":"9816_CR79","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sj.mp.4002062","volume":"12","author":"JA Gray","year":"2007","unstructured":"Gray JA, Roth BL (2007) The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12:904\u2013922","journal-title":"Mol Psychiatry"},{"key":"9816_CR80","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","volume":"70","author":"M Nakamura","year":"2009","unstructured":"Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A (2009) Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 70:829\u2013836","journal-title":"J Clin Psychiatry"},{"key":"9816_CR81","doi-asserted-by":"crossref","first-page":"P29","DOI":"10.1016\/j.clpt.2004.12.001","volume":"77","author":"A Patat","year":"2005","unstructured":"Patat A, Parks V, Raje S, Plotka A, Dietrich B (2005) Age\u2013gender study of SRA-333, a novel 5-HT1A antagonist. Clin Pharmacol Ther 77:P29","journal-title":"Clin Pharmacol Ther"},{"key":"9816_CR82","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbr.2004.11.007","volume":"159","author":"N Pitsikas","year":"2005","unstructured":"Pitsikas N, Tsitsirigou S, Zisopoulou S, Sakellaridis N (2005) The 5-HT1A receptor and recognition memory. Possible modulation of its behavioral effects by the nitrergic system. Behav Brain Res 159:287\u2013293","journal-title":"Behav Brain Res"},{"key":"9816_CR83","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1124\/jpet.105.086363","volume":"314","author":"LE Schechter","year":"2005","unstructured":"Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M, Barrett JE, Childers W (2005) Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther 314:1274\u20131289","journal-title":"J Pharmacol Exp Ther"},{"key":"9816_CR84","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mds.23895","volume":"27","author":"B Ballanger","year":"2012","unstructured":"Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, Tremblay L, Sgambato-Faure V, Broussolle E, Thobois S (2012) Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson\u2019s disease. Mov Disord 27:84\u201389","journal-title":"Mov Disord"},{"key":"9816_CR85","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pbb.2011.03.022","volume":"99","author":"TL Wallace","year":"2011","unstructured":"Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG (2011) Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav 99:130\u2013145","journal-title":"Pharmacol Biochem Behav"},{"key":"9816_CR86","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00213-004-2114-1","volume":"179","author":"AV Terry Jr","year":"2005","unstructured":"Terry AV Jr, Buccafusco JJ, Bartoszyk GD (2005) Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. Psychopharmacology 179:725\u2013732","journal-title":"Psychopharmacology"},{"key":"9816_CR87","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1248\/bpb.32.850","volume":"32","author":"H Onogi","year":"2009","unstructured":"Onogi H, Ishigaki S, Nakagawasai O, Arai-Kato Y, Arai Y, Watanabe H, Miyamoto A, Tan-No K, Tadano T (2009) Influence of memantine on brain monoaminergic neurotransmission parameters in mice: neurochemical and behavioral study. Biol Pharm Bull 32:850\u2013855","journal-title":"Biol Pharm Bull"},{"key":"9816_CR88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archneur.63.1.49","volume":"63","author":"B Reisberg","year":"2006","unstructured":"Reisberg B, Doody R, St\u00f6ffler A, Schmitt F, Ferris S, M\u00f6bius HJ (2006) A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 63:49\u201354","journal-title":"Arch Neurol"},{"key":"9816_CR89","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/S0024-3205(98)00519-0","volume":"63","author":"HS Kim","year":"1998","unstructured":"Kim HS, Park IS, Park WK (1998) NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in mice. Life Sci 63:2305\u20132311","journal-title":"Life Sci"},{"key":"9816_CR90","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0161-813X(03)00101-3","volume":"25","author":"O Nakagawasai","year":"2004","unstructured":"Nakagawasai O, Arai Y, Satoh SE, Satoh N, Neda M, Hozumi M, Oka R, Hiraga H, Tadano T (2004) Monoamine oxidase and head-twitch response in mice mechanisms of \u03b1-methylated substrate derivatives. Neurotoxicology 25:223\u2013232","journal-title":"Neurotoxicology"},{"key":"9816_CR91","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/156802610790411027","volume":"10","author":"R Raddatz","year":"2010","unstructured":"Raddatz R, Tao M, Hudkins RL (2010) Histamine H3 antagonists for treatment of cognitive deficits in CNS diseases. Curr Top Med Chem 10:153\u2013169","journal-title":"Curr Top Med Chem"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-014-9816-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10822-014-9816-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-014-9816-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:01:59Z","timestamp":1747173719000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10822-014-9816-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,26]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["9816"],"URL":"https:\/\/doi.org\/10.1007\/s10822-014-9816-1","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,26]]}}}